Literature DB >> 17703176

Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis.

Joerg Wenzel1, Bettina Peters, Sabine Zahn, Michael Birth, Kay Hofmann, Daniel Küsters, Stefan Tomiuk, Jens M Baron, Hans F Merk, Cornelia Mauch, Thomas Krieg, Thomas Bieber, Thomas Tüting, Andreas Bosio.   

Abstract

Here, we present data of a gene expression profiling approach to apply the diagnostic value and pathological significance of this method in different inflammatory skin diseases, using whole skin biopsies. Initially, SAGE was performed to identify frequent tags differentially expressed in various skin diseases. On the basis of these results, a new skin pathology-oriented PIQOR microarray was designed. Lichen planus (LP) was chosen as a model disease to evaluate this system. Controls included healthy skin, atopic dermatitis (AD), and psoriasis (Pso). Gene expression analyses using the topic-defined microarray followed by unclassified clustering was able to discriminate LP from AD and Pso. Genes significantly expressed in LP included type I IFN inducible genes and a specific chemokine expression pattern. The CXCR3 ligand, CXCL9, was the most significant marker for LP. In situ hybridization and immunohistochemistry confirmed the results and revealed that keratinocytes are type I IFN producers in LP skin lesions. Our results show that gene expression profiling using a skin-specific microarray is a reliable method to identify patients with LP in the chosen context and reflect recent models concerning the pathogenesis of this disease. Gene expression profiling might complement the diagnostic spectrum in dermatology and may provide new pathogenetic insights.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17703176     DOI: 10.1038/sj.jid.5700945

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

1.  Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption.

Authors:  M H Napimoga; E P Rocha; C A Trindade-da-Silva; A P D Demasi; E F Martinez; C G Macedo; H B Abdalla; A Bettaieb; F G Haj; J T Clemente-Napimoga; B Inceoglu; B D Hammock
Journal:  J Periodontal Res       Date:  2018-05-31       Impact factor: 4.419

2.  IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus.

Authors:  Shuai Shao; Lam C Tsoi; Mrinal K Sarkar; Xianying Xing; Ke Xue; Ranjitha Uppala; Celine C Berthier; Chang Zeng; Matthew Patrick; Allison C Billi; Joseph Fullmer; Maria A Beamer; Bethany Perez-White; Spiro Getsios; Andrew Schuler; John J Voorhees; Sung Choi; Paul Harms; J Michelle Kahlenberg; Johann E Gudjonsson
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

3.  A specific molecular signature for psoriasis and eczema.

Authors:  Susana Coimbra; Alice Santos-Silva
Journal:  Ann Transl Med       Date:  2015-04

4.  [Current developments in dermatopharmacology].

Authors:  Hans F Merk; Johannes Wohlrab
Journal:  Hautarzt       Date:  2019-12       Impact factor: 0.751

5.  IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions.

Authors:  Angelo Massimiliano D'Erme; Dagmar Wilsmann-Theis; Julia Wagenpfeil; Michael Hölzel; Sandra Ferring-Schmitt; Sonja Sternberg; Miriam Wittmann; Bettina Peters; Andreas Bosio; Thomas Bieber; Joerg Wenzel
Journal:  J Invest Dermatol       Date:  2014-12-19       Impact factor: 8.551

Review 6.  [Personalized medicine in the field of inflammatory skin diseases].

Authors:  N Garzorz-Stark; K Eyerich
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

7.  Hypothesis: sarcoidosis is a STAT1-mediated disease.

Authors:  James T Rosenbaum; Sirichai Pasadhika; Elliott D Crouser; Dongseok Choi; Christina A Harrington; Jinnell A Lewis; Carrie R Austin; Tessa N Diebel; Emily E Vance; Rita M Braziel; Justine R Smith; Stephen R Planck
Journal:  Clin Immunol       Date:  2009-05-22       Impact factor: 3.969

8.  Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.

Authors:  Matin M Imanguli; William D Swaim; Stacy C League; Ronald E Gress; Steven Z Pavletic; Frances T Hakim
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

9.  Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation?

Authors:  Marina Scheler; Joerg Wenzel; Thomas Tüting; Osamu Takikawa; Thomas Bieber; Dagmar von Bubnoff
Journal:  Am J Pathol       Date:  2007-11-30       Impact factor: 4.307

Review 10.  The influence of interferon on healthy and diseased skin.

Authors:  Grace A Hile; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  Cytokine       Date:  2018-12-06       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.